Palvella Therapeutics
PVLA
29 hedge funds and large institutions have $37.4M invested in Palvella Therapeutics in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
135% more capital inflows, than outflows
Capital inflows: $2.23M | Capital outflows: $950K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
12% more funds holding
Funds holding: 26 → 29 (+3)
1.77% more ownership
Funds ownership: 45.78% → 47.55% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$1.29M |
| 2 |
Tekla Capital Management
Boston,
Massachusetts
|
+$495K |
| 3 |
Morgan Stanley
New York
|
+$123K |
| 4 |
Renaissance Technologies
New York
|
+$71.6K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$57.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$687K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$121K |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$100K |
| 4 |
Virtu KCG Holdings
New York
|
-$20K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$17K |
PVLA Hedge Fund Activity: Q3 2016 in Review
29 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2016, worth a combined $37.4M — up 18% from $31.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PVLA positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was BVF Inc, adding an estimated $1.29M. The largest seller was Omega Fund Management, cutting an estimated $687K.
- 29 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2016, up from 26 in Q2 2016.
- Funds reported $37.4M of Palvella Therapeutics stock for Q3 2016, up 18% quarter-over-quarter.
- 7 funds opened new Palvella Therapeutics positions in Q3 2016 and 3 closed out, a net change of +4 holders.
- The largest Palvella Therapeutics buyer in Q3 2016 was BVF Inc, an estimated $1.29M added.
- The largest Palvella Therapeutics seller in Q3 2016 was Omega Fund Management, an estimated $687K sold.
Based on aggregated 13F filings for Q3 2016.